(S)-2-chloro-7-(3-fluorophenoxy)-6,7-dihydro-5H-cyclopenta[b]pyridine | 1138558-17-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (S)-2-chloro-7-(3-fluorophenoxy)-6,7-dihydro-5H-cyclopenta[b]pyridine
• CAS: 1138558-17-4
• 化学式: C₁₄H₁₁ClFNO
• 分子量: 263.699
• InChiKey: VDWUYKVGHOBLGV-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.94
• 重原子数：
  18.0
• 可旋转键数：
  2.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  22.12
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  (S)-2-chloro-7-(3-fluorophenoxy)-6,7-dihydro-5H-cyclopenta[b]pyridine 、 N-Boc-哌嗪 在 tris-(dibenzylideneacetone)dipalladium(0) 、 sodium t-butanolate 、 2-二环己膦基-2'-(N,N-二甲胺)-联苯 作用下， 以 甲苯 为溶剂， 生成
  参考文献：
  名称：

  Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity

  摘要：

  Based on our original pyrazine hit, CP-0809101, novel conformationally-restricted 5HT2c receptor agonists with 2-piperazin-azaindane scaffold were designed. Synthesis and structure-activity relationship (SAR) studies are described with emphasis on optimization of the selectivity against 5HT2a and 5HT2b receptors with excellent 2c potency. Orally-active and selective compounds were identified with dose responsive in vivo efficacy in our pre-clinical food intake model. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.112
• 作为产物：
  描述：

  (R)-2-氯-6,7-二氢-5H-环戊[b]吡啶-7-醇 、 3-氟苯酚 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 甲苯 为溶剂， 生成 (S)-2-chloro-7-(3-fluorophenoxy)-6,7-dihydro-5H-cyclopenta[b]pyridine
  参考文献：
  名称：

  Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity

  摘要：

  Based on our original pyrazine hit, CP-0809101, novel conformationally-restricted 5HT2c receptor agonists with 2-piperazin-azaindane scaffold were designed. Synthesis and structure-activity relationship (SAR) studies are described with emphasis on optimization of the selectivity against 5HT2a and 5HT2b receptors with excellent 2c potency. Orally-active and selective compounds were identified with dose responsive in vivo efficacy in our pre-clinical food intake model. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.112